Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
175 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015', provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 10 Therapeutics Development 11 Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 11 Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 12 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 13 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes 15 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 20 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Investigation by Universities/Institutes 22 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 23 Amarantus Bioscience Holdings, Inc. 23 AnGes MG, Inc. 24 AstraZeneca Plc 25 Bayer AG 26 Biosidus S.A. 27 Biscayne Pharmaceuticals, Inc. 28 Capricor Therapeutics, Inc. 29 Eagle Pharmaceuticals, Inc. 30 Eli Lilly and Company 31 Gilead Sciences, Inc. 32 Hemostemix Ltd 33 Human Stem Cells Institute 34 Juventas Therapeutics, Inc. 35 Lacer, S.A. 36 Lee's Pharmaceutical Holdings Limited 37 Lonestar Heart, Inc. 38 MedImmune, LLC 39 Merck & Co., Inc. 40 Miltenyi Biotec GmbH 41 Multi Gene Vascular Systems Ltd 42 Nuo Therapeutics, Inc. 43 Pluristem Therapeutics Inc. 44 The Medicines Company 45 ViroMed Co., Ltd. 46 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 ACP-01 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ALD-201 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 AMRS-001 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 anacetrapib - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 BAY-606583 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 beperminogene perplasmid - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 BIS-5409 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 bivalirudin - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 bivalirudin - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 BQ-123 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 C2 ceramide - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 C6 ceramide - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 cangrelor - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 CAP-1002 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Cryocell - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 evacetrapib - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Gemacell - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Gene Therapy to Activate VEGF for Ischemia - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 ISIS-APOARx - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 JVS-100 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 LA-419 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 MEDI-6012 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 MultiGeneGraft - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 MZ-004 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 neovasculgen - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 PLX-PAD - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Protein for Cardiovascular Diseases - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Proteins for Ischemic Heart Disease - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 ranolazine ER - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 rivaroxaban - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Small Molecule for Coronary Artery Disease - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 Stem Cell Therapy for Cardiovascular Disease - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 VM-202 - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 ZK-001 - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 120 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 162 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 165 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 166 Featured News & Press Releases 166 Sep 01, 2015: MATRIX Trial Results Presented at Hot Line Session of ESC Congress 2015 and Simultaneously Published in The New England Journal of Medicine 166 Sep 01, 2015: Analysis from CHAMPION PHOENIX Trial Highlight the Efficacy of Cangrelor among Patients undergoing PCI via the Radial Approach 167 Jul 23, 2015: Eagle Pharmaceuticals' RTU Bivalirudin NDA Accepted for Filing 167 Jun 22, 2015: FDA approves new antiplatelet drug used during heart procedure 168 May 20, 2015: Eagle Pharmaceuticals Submits NDA for Ready-to-Use Bivalirudin to FDA 168 Apr 15, 2015: FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor 169 Mar 30, 2015: The Medicines Company Receives European Commission Approval for Hospital Acute Care Product : KENGREXAL 169 Mar 11, 2015: The Medicines Company Presents new data on Cangrelor at 2015 American College of Cardiology Scientific Sessions in San Diego 171 Jan 07, 2015: Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services 172 Nov 14, 2014: The Medicines Company to Present New Data on Investigational Antiplatelet Agent Cangrelor at 2014 AHA Annual Scientific Sessions in Chicago 172 Appendix 174 Methodology 174 Coverage 174 Secondary Research 174 Primary Research 174 Expert Panel Validation 174 Contact Us 174 Disclaimer 175
List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015 11 Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H2 2015 12 Number of Products under Development by Companies, H2 2015 14 Number of Products under Investigation by Universities/Institutes, H2 2015 15 Comparative Analysis by Late Stage Development, H2 2015 16 Comparative Analysis by Clinical Stage Development, H2 2015 17 Comparative Analysis by Early Stage Development, H2 2015 18 Comparative Analysis by Unknown Stage Development, H2 2015 19 Products under Development by Companies, H2 2015 20 Products under Development by Companies, H2 2015 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2015 22 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015 23 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H2 2015 24 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H2 2015 25 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H2 2015 26 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biosidus S.A., H2 2015 27 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015 28 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics, Inc., H2 2015 29 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eagle Pharmaceuticals, Inc., H2 2015 30 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eli Lilly and Company, H2 2015 31 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H2 2015 32 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Ltd, H2 2015 33 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2015 34 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H2 2015 35 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H2 2015 36 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 37 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H2 2015 38 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H2 2015 39 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H2 2015 40 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H2 2015 41 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015 42 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H2 2015 43 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H2 2015 44 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H2 2015 45 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H2 2015 46 Assessment by Monotherapy Products, H2 2015 47 Number of Products by Stage and Target, H2 2015 49 Number of Products by Stage and Mechanism of Action, H2 2015 51 Number of Products by Stage and Route of Administration, H2 2015 53 Number of Products by Stage and Molecule Type, H2 2015 55 Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H2 2015 120 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2015 162 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..1), H2 2015 163 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..2), H2 2015 164 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2015 165
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
